NEI Research News

Neuroscientists at Johns Hopkins Medicine have shown that intrinsically-photosensitive retinal ganglion cells use two different pathways at the same time to transmit electrical “vision” signals to the brain.

Researchers combined retinal imaging, genetics and big data to estimate how likely a person is to develop eye and systemic diseases in the future.

NEI researchers improved a crucial step in the production of retinal pigment epithelium (RPE), a tissue they grow in the lab from patient blood cells and are testing in a clinical trial as treatment for AMD.

The September 14 workshop brought together multidisciplinary experts in extracellular vesicles – cell-secreted nanoparticles that mediate cell-cell communication.

Scientists have identified a protein in the visual system of mice that appears to be key for stabilizing the body’s circadian rhythms by buffering the brain’s response to light.

In a comparative analysis across animals of the many cell types in the retina, researchers concluded that most cell types have an ancient evolutionary history.

This year, the Food and Drug Administration (FDA) approved Syfovre (pegcetacoplan) and Izervay (avacincaptad pegol), the very first drugs for treating geographic atrophy (GA), also known as late-stage “dry” age-related macular degeneration (AMD).

A longstanding member of the NEI/NIH community, Emily Chew, M.D., has been promoted to the title of NIH Distinguished Investigator for her tireless and prolific work as a care provider and clinical trialist.

A multidisciplinary team led by researchers at the Schepens Eye Research Institute of Mass Eye and Ear has identified a promising new strategy for glaucoma cell replacement therapy.

NEI-funded investigators at Washington University in St. Louis discovered a potential new treatment approach to diabetic retinopathy, one of the most common causes of vision loss in the U.S.